Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, vol.395, pp.497-506, 2020. ,
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic, Trends Pharmacol Sci, vol.41, pp.363-382, 2020. ,
Adjunct immunotherapies for the management of severely ill COVID-19 patients, Cell Rep Med, vol.1, p.100016, 2020. ,
URL : https://hal.archives-ouvertes.fr/inserm-02555342
Human FOXP3(+) Regulatory T cell heterogeneity and function in autoimmunity and cancer, Immunity, vol.50, pp.302-316, 2019. ,
A Distinct Function of Regulatory T Cells in Tissue Protection, Cell, vol.162, pp.1078-1089, 2015. ,
Dysregulation of immune response in patients with COVID-19 in Wuhan, China, Clin Infect Dis, 2020. ,
The Laboratory tests and host immunity of COVID-19 patients with different severity of illness, JCI Insight, vol.5, p.137799, 2020. ,
Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest, vol.130, pp.2620-2629, 2020. ,
High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients, Cell Mol Immunol, vol.17, pp.650-652, 2020. ,
T-cell hyperactivation and paralysis in severeCOVID-19 infection revealed by single-cell analysis, 2020. ,
Middle east respiratory syndrome coronavirus efficiently infects human primary t lymphocytes and activates the extrinsic and intrinsic apoptosis pathways, J Infect Dis, vol.213, pp.904-914, 2016. ,
Role of regulatory t cells in coronavirus-induced acute encephalitis, Virology, vol.385, pp.358-367, 2009. ,
but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters, Nat Med, vol.15, pp.930-939, 2009. ,
Circulating regulatory t cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk, Obesity, vol.21, pp.461-468, 2013. ,
Type 1 diabetes immunotherapy using polyclonal regulatory T cells, Sci Transl Med, vol.7, pp.315-189, 2015. ,
Past, present, and future of regulatory t cell therapy in transplantation and autoimmunity, Front Immunol, vol.10, p.43, 2019. ,
Low-dose interleukin 2 in patients with type 1 diabetes: A phase 1/2 randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, vol.1, pp.295-305, 2013. ,
A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism, Nat Med, vol.24, pp.1005-1014, 2018. ,
In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression, J Exp Med, vol.206, pp.751-760, 2009. ,
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4, Science, vol.332, pp.600-603, 2011. ,
CTLA-4Ig) treatment reduces t cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis, Rheumatology, vol.55, pp.710-720, 2016. ,
Regulatory T-cell dynamics with abatacept treatment in rheumatoid arthritis, Int Rev Immunol, vol.37, pp.206-214, 2018. ,
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs, Semin Arthritis Rheum, vol.50, pp.564-570, 2020. ,
Hospital admissions in inflammatory rheumatic diseases during the COVID-19 pandemic: incidence and role of disease modifying agents, vol.2020 ,
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs, Ann Rheum Dis, 2020. ,